Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2025Age and AgeingOpen Access

Integrating Pathological Diagnosis And Clinical Staging With Advances In AD Biomarkers

View Full Paper
Ask AI
Bookmark
Share

Authors

AOAntoinette O’Connor

Discussion

Loading...

Member takes

Overview

This analysis demonstrates improved diagnostic performance of biomarkers in Alzheimer's disease, indicating enhanced clinical outcomes and guidelines for diagnosis and prognosis.

Key Points

  • Blood based biomarkers like plasma p-tau217 yield strong diagnostic performance, achieving an AUC of 0.91, crucial for Alzheimer's diagnosis.
  • The integration of cerebrospinal fluid analysis and blood tests, as outlined in new diagnostic criteria, enhances clinical practice in Alzheimer’s care.
  • Updated multidisciplinary consensus guidelines stress the need for biomarker-supported approaches to improve diagnosis and treatment pathways.
  • Advancements in Alzheimer's biomarkers promise better prognostic capabilities and more precise diagnosis, thereby supporting patient outcomes.

Cite This Study

Antoinette O’Connor (2025) studied this question.

synapsesocial.com/papers/69402a652d562116f2901af5https://doi.org/10.1093/ageing/afaf318.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Can the integration of blood-based biomarkers into Alzheimer’s disease diagnosis revolutionize the field?2026
  2. 2[Current Status and Future Perspectives of Biomarkers in Alzheimer's Disease Diagnosis].2025
  3. 3The Role of Blood-Based Biomarkers in Transforming Alzheimer’s Disease Research and Clinical Management: A Review2025 · 18 citations
  4. 4Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics2024 · 13 citations
  5. 5Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease2024 · 9 citations